Information Provided By: 
Fly News Breaks for September 27, 2016
ARRY
Sep 27, 2016 | 06:18 EDT
JPMorgan analyst Anupam Rama raised his price target for Array BioPharma to $8 saying he's increasingly confident on the likelihood of encorafenib/binimetinib approval for BRAF+ melanoma following yesterday's dataset. The analyst sees a $325M-plus opportunity in BRAF melanoma in the U.S. alone and reiterates an Overweight rating on shares of Array.
News For ARRY From the Last 2 Days
ARRY
Apr 24, 2024 | 11:02 EDT
Wells Fargo notes that a group of seven domestic solar product makers, including First Solar (FSLR), filed a petition to levy anti-dumping and countervailing duties on solar imports from Cambodia, Malaysia, Thailand and Vietnam, looking for duties ranging from 70.4% to 271.5%. The firm, which included the "important reminder" that "this is just a petition," says the uncertainty created by the petition is "incrementally positive" for First Solar and negative for Canadian Solar (CSIQ), Array Technologies (ARRY) and Nextracker (NXT).
